Trial Profile
A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Sep 2019
Price :
$35
*
At a glance
- Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
- Indications Bipolar I disorders; Psychotic disorders; Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms ENLIGHTEN-Early
- Sponsors Alkermes plc
- 26 Jul 2019 Planned number of patients changed from 350 to 425.
- 26 Jul 2019 Planned End Date changed from 1 Nov 2019 to 1 Dec 2021.
- 26 Jul 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2021.